What clinical findings are most consistent with cholinesterase (organophosphate) toxicity?

Clinical Findings Most Consistent with Cholinesterase Toxicity

Cholinesterase toxicity presents with a characteristic triad of muscarinic excess (bradycardia, bronchospasm, bronchorrhea, miosis, hypersalivation, lacrimation, urination, diarrhea, vomiting, diaphoresis), nicotinic excess (fasciculations progressing to paralysis), and CNS effects (altered mental status, seizures, respiratory depression). 1

Muscarinic Manifestations (Parasympathetic Excess)

The most prominent and consistent findings are muscarinic effects, which dominate the clinical picture in approximately 83% of cases requiring intensive care 2:

• Bronchorrhea and bronchospasm - excessive respiratory secretions with airway constriction
• Bradycardia - can progress to heart block and arrhythmias
• Miosis - pinpoint pupils (classic finding)
• Hypersalivation and lacrimation - excessive secretions from glands
• Urination and defecation - loss of bowel/bladder control
• Diaphoresis - profuse sweating
• Emesis - nausea and vomiting with abdominal cramping

These muscarinic features are often remembered by the mnemonic "SLUDGE" (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) or "DUMBELS" (Diarrhea, Urination, Miosis, Bronchorrhea/Bronchospasm, Emesis, Lacrimation, Salivation) 1.

Nicotinic Manifestations

Nicotinic effects occur in approximately 17% of severe cases 2 and follow a characteristic progression:

• Early fasciculations - involuntary muscle twitching, particularly visible in large muscle groups
• Muscle weakness - progressing to flaccid paralysis
• Respiratory muscle paralysis - leading to ventilatory failure (57% of ICU cases) 2
• Initial tachycardia and hypertension - from sympathetic ganglia stimulation, though this is typically brief and followed by muscarinic bradycardia 3
• Mydriasis - pupil dilation (paradoxically can occur alongside miosis from competing effects)

Central Nervous System Effects

CNS manifestations occur in approximately 78% of severe cases 2:

• Altered mental status - anxiety, confusion, disorientation progressing to coma
• Seizures - can rapidly progress to status epilepticus
• Central respiratory depression - independent of peripheral muscle paralysis
• Coma - in severe exposures

Route-Specific Presentation Patterns

The clinical presentation varies by exposure route 3:

Vapor/inhalation exposure:

• Respiratory symptoms appear first (shortness of breath, wheezing, bronchorrhea)
• Rapid progression to cardiorespiratory collapse within minutes
• More immediate life threat

Dermal exposure:

• Local muscle twitching at contact site initially
• More gradual progression of systemic symptoms
• Delayed onset of respiratory failure
• Higher contamination risk to healthcare workers

Laboratory Confirmation

Cholinesterase levels provide objective confirmation 2, 4:

• Serum cholinesterase < 200 U/L predicts severe toxicity and intermediate syndrome development 5
• Levels < 265 U/L associated with fatal outcomes 4
• > 50% reduction from baseline indicates significant exposure 6
• Red blood cell cholinesterase more accurately reflects CNS acetylcholinesterase activity 3

Critical Pitfalls to Recognize

Biphasic cardiovascular response: Initial nicotinic-mediated tachycardia and hypertension can mislead clinicians before the dominant muscarinic bradycardia and hypotension emerge 3. Don't be falsely reassured by early tachycardia.

Intermediate syndrome: Develops 24-96 hours after initial cholinergic crisis in 22-65% of severe cases 2, 5. Presents with proximal muscle weakness, respiratory muscle paralysis, and cranial nerve palsies despite resolution of initial cholinergic symptoms. This is a distinct clinical entity requiring prolonged mechanical ventilation.

Delayed polyneuropathy: Can occur weeks after exposure, particularly with certain organophosphates 7. Presents as distal sensory-motor neuropathy.

Competing pupillary effects: While miosis is classic, mydriasis from nicotinic effects can occur, creating confusion 1, 3. The presence of other cholinergic signs remains diagnostic.

Severity Assessment

The combination of findings predicts outcomes 2:

• Bronchial secretions requiring mechanical ventilation (83% of ICU admissions)
• Altered consciousness (78% of ICU admissions)
• Flaccid paralysis (57% of ICU admissions)
• APACHE II score ≥ 26 predicts mortality with 95% sensitivity and 100% specificity 2

The clinical diagnosis rests on recognizing the pattern of cholinergic excess across multiple organ systems, with muscarinic effects being most consistent and prominent, supported by depressed cholinesterase levels when available 1, 3.